Slide 1: Insulet Corporation Q2'24 Earnings
Mattie Podder since 2010 Insulet Corporation Q2'24 Earnings August 8, 2024
Slide 2: Forward Looking Statement
Forward Looking Statement This presentation contains forward-looking statements regarding, among other things, future operating and financial performance, product success and efficacy, the outcome of studies and trials and the approval of products by regulatory bodies. These forward-looking statemen
Slide 3: Non-GAAP Financial Measures
Non-GAAP Financial Measures The Company uses the following non-GAAP financial measures: • Constant currency revenue growth, which represents the change in revenue between current and prior year periods using the exchange rate in effect during the applicable prior year period. Insulet presents consta
Slide 4: Insulet Abbreviations and Acronyms
Insulet Abbreviations and Acronyms Business specific ADA American Diabetes Association MDI Multiple Daily Injections AID Automated Insulin Delivery NCS New Customer Starts Bps Basis Points QOL Quality of Life CGM Continuous Glucose Monitoring T2D Type 2 Diabetes FMR Full Market Release YoY Year-over
Slide 5: Financial Highlights
Financial Highlights Q2'241 Revenue Performance Q2'24 Other Financial Highlights Total Company $488.5M Gross Margin of 67.7% • Up 90 bps compared to prior year an increase of 23.2%, or 23.4% • Includes a charge of $13.5 million in constant currency1 relating to certain inventory components which we
Slide 6: Recent Strategic Highlights - Q2'24
Recent Strategic Highlights - Q2'24 U.S. International Clinical & Other Launched FMR of Omnipod 5 • International full market releases of Presented at ADA data from our integrated with Dexcom's G7 sensor Omnipod 5 integrated with: SECURE-T2D pivotal trial demonstrating ◦ Dexcom’s G6 sensor in the Ne
Slide 7: Revenue Performance - Q2'24
Revenue Performance - Q2'24 Total Revenue and Growth Rates1 U.S. Omnipod Revenue and Growth Rates1 Int'l Omnipod Revenue and Growth Rates1 Total Omnipod Revenue and Growth Rates1 7 1. Growth rates are on a YoY basis and are in constant currency, $s in millions. See description of non-GAAP financial
Slide 8: Margin Performance - Q2'24
Margin Performance - Q2'24 Gross Profit & Margin (adjusted)1 Operating Income & Margin (adjusted)1 $s in Millions $s in Millions 8 1. For the periods indicated, gross profit and operating income are adjusted to exclude certain items. Refer to non-GAAP reconciliations in appendix for additional infor
Slide 9: Key Commercial Metrics - Q2'24
~85% Majority of U.S. NCS were MDI of international NCS were Omnipod 5 Key Commercial ~25% Vast Majority Metrics – of U.S. NCS were type 2 of U.S. volume Q2'24 through pharmacy 9 Note: Some commercial metrics are directional estimates derived from various internal and external data sources.
Slide 10: Product Development Status - Q2'24
Product Development Status - Q2'24 Legend U.S. Commercial Product Regulatory Innovation Pipeline International Strategy Development Classic Omnipod Omnipod DASH Omnipod 5 w/ U.S. FMR August 2022 CE Mark September 2022 Dexcom G6 U.K. FMR in June 2023 Australia TGA approval in July 2024 Germany FMR in
Slide 11: Guidance Highlights - 2024
Guidance Highlights - 2024 Revenue Guidance1,2 Margin Guidance Assumptions & Drivers Expect NCS and revenue ramp in 2H'24 Q3'24 FY 2024 FY 2024 FY 2024 driven by cascade of innovations Revenue Revenue Raise Gross Margin Raise Operating Margin Raise NCS update 68% to 69% ~14% • Global NCS YoY growth
Slide 12: Appendix
Appendix Insulet
Slide 13: Non-GAAP Reconciliation - Revenue Guidance
Non-GAAP Reconciliation - Revenue Guidance Q3 2024 Revenue Growth GAAP Currency Impact Constant Currency U.S. Omnipod 21% to 24% —% 21% to 24% International Omnipod 20% to 23% (1)% 21% to 24% Total Omnipod 21% to 24% —% 21% to 24% Drug Delivery (70)% to (65)% —% (70)% to (65)% Total Revenue 18% to 2
Slide 14: Reconciliation of Historical Non-GAAP Measures
Reconciliation of Historical Non-GAAP Measures FY 2023 % of FY 2022 % of FY 2021 % of FY 2020 % of Q2'2024 % of Q2'2023 % of Revenue Revenue Revenue Revenue Revenue Revenue Total Revenue GAAP Growth Rate 30.0% 18.8% 21.5% 22.5% 23.2% 32.4% Less: Currency Impact 0.4% (3.7) % 1.8% 0.6% (0.2) % 0.2% Co